# Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer

> **NCT03950362** · PHASE2 · UNKNOWN · sponsor: **Institut Paoli-Calmettes** · enrollment: 67 (estimated)

## Conditions studied

- Non-muscle-invasive Bladder Cancer

## Interventions

- **DRUG:** Avelumab
- **DEVICE:** Radiotherapy

## Key facts

- **NCT ID:** NCT03950362
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-15
- **Primary completion:** 2023-06-15
- **Final completion:** 2024-06-15
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2019-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03950362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03950362, "Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03950362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*